NEW YORK (GenomeWeb News) - Biogen Idec and Alnylam will jointly develop RNAi therapeutics to treat progressive multifocal leukoencephalopathy, the companies said today.
 
Biogen Idec will finance all research and development activities and Alnylam will receive an upfront payment of $5 million.
 
Alnylam will also receive more than $51 million in milestone payments, royalties, and utilization fees if the collaboration successfully develops any therapeutic products.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.